BackOrchestra BioMed Holdings Overview

Orchestra BioMed Holdings Operating Income

Track Orchestra BioMed Holdings's operating income ($-58M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly Operating Income

$-22356000.00
↑ 15.67% YoY

As of Jun 30, 2026

Annual Operating Income (TTM)

$-57991000.00
↓ 18.63% YoY

Trailing 12 months ending Jun 30, 2026

Average Operating Income (Comparison Companies)

Operating Income History

Operating Income Comparison

Annual Operating Income Growth Rate (%)

Annual Operating Income Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin

Orchestra BioMed Holdings (OBIO) FAQ

As of the most recent data (June 2026), OBIO shows a operating income of $-58M. That compares with $-71M in the prior-year period — up 18.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, OBIO's operating income is now $-58M (was $-71M) — a 18.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Orchestra BioMed Holdings is outperforming or lagging.

Tracking OBIO's operating income over time shows whether Orchestra BioMed Holdings is scaling, shrinking, or reshaping that part of the business. The current reading is $-58M That compares with $-71M in the prior-year period — up 18.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Orchestra BioMed Holdings's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-58M) with ownership activity and broader fundamentals.